BiotechTube

Vusolimogene Oderparepvec (VO) + Pembrolizumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angiosarcoma

Conditions

Angiosarcoma, Angiosarcoma, Adult

Trial Timeline

Jan 9, 2026 → Oct 31, 2029

NCT ID
NCT06898970

About Vusolimogene Oderparepvec (VO) + Pembrolizumab

Vusolimogene Oderparepvec (VO) + Pembrolizumab is a phase 2 stage product being developed by Replimune for Angiosarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06898970. Target conditions include Angiosarcoma, Angiosarcoma, Adult.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06898970Phase 2Recruiting

Competing Products

6 competing products in Angiosarcoma

See all competitors
ProductCompanyStageHype Score
EribulinEisaiPhase 2
52
Avelumab + PaclitaxelMerckPhase 2
52
Pembrolizumab plus LenvatinibMerckPhase 2
52
Pazopanib + PaclitaxelNovartisPhase 2
52
regorafenibBayerPhase 2
49
AGEN2034 + AGEN1884AgenusPhase 2
44

Other Products from Replimune

Vusolimogene Oderparepvec + Nivolumab + Nivolumab + Relatlimab + Pembrolizumab + Single-agent chemotherapyPhase 3
69
RP2 + Ipilimumab + NivolumabPhase 2/3
57
RP2 + Bevacizumab + Atezolizumab + Durvalumab + RP2 MonotherapyPhase 2
44
RP2 + Pegfilgrastim + FilgrastimPhase 2
44
RP2 InjectionPhase 2
44